ABIVAX to participate in the upcoming Jefferies Global Healthcare Conference in London and the German Equity Forum in Frankfurt

Paris, France November 12, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral and vaccine therapies for diseases like HIV/AIDS and the hepatitis B virus (HBV), today announced that its CEO, Prof. Dr. Hartmut Ehrlich will participate in the Jefferies 2015 Global Healthcare Conference in London on November 18 and 19, 2015.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41